Novel and Combination Therapies for Hepatitis C Virus, An Issue of Clinics in Liver Disease, 1st Edition
Author :
Paul J. Pockros
Dr. Pockros has created a clinically focused issue based on the CONO 2012 meeting, whereby he was able to have those presenters write articles for his issue. Therefore, the content for HCV in this issue reflects the most current knowledge. The issue ...view more
Dr. Pockros has created a clinically focused issue based on the CONO 2012 meeting, whereby he was able to have those presenters write articles for his issue. Therefore, the content for HCV in this issue reflects the most current knowledge. The issue is focused on basic/current information, current therapy and special populations, triple and quad combination therapies in development, and an article on second generation protease inhibitors. The reader can expect that this issue will provide thorough clinical reviews on the most current therapeutic options for HCV.
Dr. Pockros has created a clinically focused issue based on the CONO 2012 meeting, whereby he was able to have those presenters write articles for his issue. Therefore, the content for HCV in this issue reflects the most current knowledge. The issue is focused on basic/current information, current therapy and special populations, triple and quad combination therapies in development, and an article on second generation protease inhibitors. The reader can expect that this issue will provide thorough clinical reviews on the most current therapeutic options for HCV.
Author Information
By Paul J. Pockros, MD, Scripps Research Institute, La Jolla, CA
https://www.us.elsevierhealth.com/novel-and-combination-therapies-for-hepatitis-c-virus-an-issue-of-clinics-in-liver-disease-9781455771127.html7105Novel and Combination Therapies for Hepatitis C Virus, An Issue of Clinics in Liver Diseasehttps://www.us.elsevierhealth.com/media/catalog/product/9/7/9781455771127.jpg64.3498.99USDInStock/Medicine/Hepatology/Clinics/Clinics1434388725525504113841826925145120Dr. Pockros has created a clinically focused issue based on the CONO 2012 meeting, whereby he was able to have those presenters write articles for his issue. Therefore, the content for HCV in this issue reflects the most current knowledge. The issue is focused on basic/current information, current therapy and special populations, triple and quad combination therapies in development, and an article on second generation protease inhibitors. The reader can expect that this issue will provide thorough clinical reviews on the most current therapeutic options for HCV. Dr. Pockros has created a clinically focused issue based on the CONO 2012 meeting, whereby he was able to have those presenters write articles for his issue. Therefore, the content for HCV in this issue reflects the most current knowledge. The issue is focused on basic/current information, current therapy and special populations, triple and quad combination therapies in development, and an article on second generation protease inhibitors. The reader can expect that this issue will provide thorough clinical reviews on the most current therapeutic options for HCV.00add-to-cart97814557711272012ProfessionalBy Paul J. Pockros, MD20131Book152w x 229h (6.00" x 9.00")Elsevier0Dec 2, 2012IN STOCK - This may take up to 5 business days to shipBy <STRONG>Paul J. Pockros</STRONG>, MD, Scripps Research Institute, La Jolla, CAClinicsClinicsThe Clinics: Internal MedicineNoNoNoNoPlease SelectPlease SelectPlease Select
